From: Does antithrombotic therapy improve survival with colorectal cancer?
Characteristic | Overall, n = 710 | Antithrombotic therapy, n = 246 | Control, n = 464 | p value |
---|---|---|---|---|
Age (years, mean ± SD) | 73.8 ± 7.8 | 68.6 ± 11.6 | 0.01 | |
Gender (n, %) | Male | 183(74.3) | 276 (59.4) | |
Female | 63 (25.7) | 188 (40.6) | 0.01 | |
BMI (kg/m2, mean ± SD) | 22.3 ± 3.4 | 23.6 ± 6.7 | 0.57 | |
ASA score (n, %) | 1 | 0 (0) | 63 (13.5) | |
2 | 0 (0) | 366 (78.9) | ||
3 | 225 (91.5) | 22 (5.0) | ||
4 | 21 (8.5) | 13 (2.6) | 0.01 | |
Comorbidities (n, %) | ≤1 | 18 (7.3) | 98 (21.1) | |
>1 | 228 (92.7) | 366 (78.9) | 0.02 | |
Tumor location (n, %) | Right side | 103 (41.5) | 209 (45.0) | |
Left side | 67 (27.6) | 102 (22.0) | ||
Rectum | 76 (30.9) | 153 (33.0) | 0.37 | |
Extended resection (n, %) | Yes | 22 (8.9) | 63 (13.5) | |
No | 224 (91.1) | 401 (86.5) | 0.07 | |
Laproscopic surgery (n, %) | Yes | 52 (21.1) | 121 (26.0) | |
No | 194 (78.9) | 343 (74.0) | 0.14 | |
Chemotherapy (n, %) | Yes | 120 (48.7) | 268 (57.7) | |
No | 126 (51.3) | 196 (42.3) | 0.02 | |
Recurrence (n, %) | Yes | 36 (14.6) | 98 (21.1) | |
No | 210 (85.4) | 366 (78.9) | 0.03 | |
T stage (n, %) | 0 | 9 (3.6) | 11 (2.3) | |
1 | 50 (20.3) | 82 (17.6) | ||
2 | 34 (13.8) | 44 (9.5) | ||
3 | 100 (40.6) | 198 (42.7) | ||
4 | 53 (21.7) | 128 (27.9) | 0.15 | |
N stage (n, %) | 0 | 146 (59.3) | 281 (60.5) | |
1 | 60 (24.3) | 103 (22.2) | ||
2 | 33 (13.4) | 63 (13.5) | ||
3 | 7 (3.0) | 16 (3.8) | 0.9 | |
M factor (n, %) | 0 | 220 (89.4) | 396 (85.3) | |
1 | 26 (10.6) | 67 (14.7) | 0.14 | |
The number of lymph node metastasis (n, %) | 1.59 ± 3.15 | 1.47 ± 2.81 | 0.6 | |
Lymph node metastasis (n, %) | Yes | 103 (41.8) | 179 (38.5) | |
No | 143 (58.2) | 285 (61.5) | 0.39 | |
Stage (n, %) | 0 | 9 (3.6) | 11 (2.4) | |
I | 65 (26.4) | 114 (24.6) | ||
II | 65 (26.4) | 142 (30.6) | ||
IIIa | 54 (21.9) | 87 (18.7) | ||
IIIb | 21 (8.5) | 37 (8.0) | ||
IV | 32 (13.2) | 72 (15.7) | 0.59 | |
ly (n, %) | 0 | 67 (27.2) | 106 (22.8) | |
1 | 140 (56.9) | 252 (54.3) | ||
2 | 33 (13.4) | 89 (19.2) | ||
3 | 6 (2.5) | 16 (3.7) | 0.15 | |
v (n, %) | 0 | 116 (47.2) | 202 (43.5) | |
1 | 62 (25.2) | 118 (25.4) | ||
2 | 61 (24.8) | 121 (26.1) | ||
3 | 7 (2.8) | 22 (5.0) | 0.55 | |
R (n, %) | 0 | 222 (90.2) | 399 (86.0) | |
1 | 24 (9.8) | 64 (14.0) | 0.22 | |
Histrogical type (n, %) | Well | 212 (86.2) | 398 (84.3) | |
Other | 34 (13.8) | 66 (15.7) | 0.88 | |
Poorly differentiated adenocarcinoma (n, %) | Yes | 18 (7.3) | 43 (9.2) | |
No | 228 (92.7) | 421 (90.8) | 0.37 | |
Mucinous adenocarcinoma (n, %) | Yes | 19 (7.7) | 31 (6.7) | |
No | 227 (92.3) | 433 (93.3) | 0.61 |